FDA to Review Olanzapine-Samidorphan Combo (Again); Ketamine for PTSD?

January 7, 2021January 7, 2021 SCofA 8 Views

(MedPage Today) — After an initial positive review from an advisory panel but subsequent FDA rejection in November 2020, the FDA accepted Alkermes’ resubmission of its new drug application for ALKS 3831, a combination olanzapine/samidorphan treatment…
Read More

← How Much Alcohol Is Too Much?
Pandemic Packed a Year of Distress Into 1 Month →